Pro-fibrotic effect of IL-6 via aortic adventitial fibroblasts indicates IL-6 as a treatment target in Takayasu arteritis

Clin Exp Rheumatol. 2018 Jan-Feb;36(1):62-72. Epub 2017 Jul 6.

Abstract

Objectives: This study aimed to clarify potential mechanism of IL-6 involved in adventitial fibrosis via adventitial fibroblast in Takayasu arteritis (TAK).

Methods: Immunohistochemistry and double-labelled immunofluorescence were performed on vascular tissue from patients with TAK and controls. Human aorta adventitial fibroblast (AAF) was cultured and stimulated with interleukine 6 (IL-6)/IL-6 receptor (IL-6R). Real-time PCR, western blot, enzyme-linked immunosorbent assays, chromatin immunoprecipitation (ChIP) and reporter assay were conducted in vitro experiments to determine effect of IL-6/IL-6R on AAF.

Results: The expression of IL-6, IL-6R, collagen I, collagen III, fibronectin, α-smooth muscle actin (α-SMA), and transforming growth factor (TGF-β) in TAK arteries was significantly higher than that in the normal arteries. Co-localisation of α-SMA and IL-6 and a positive correlation between their expression were observed in local lesions. In vitro experiments, collagen I, collagen III, fibronectin, α-SMA, and TGF-β expression increased significantly after stimulation and this fibrogenesis of AAFs was induced in TGF-β-dependent and -independent manners. Additionally, phosphorylation of JAK2, STAT3 and Akt was significantly enhanced both in IL-6/IL-6R-treated AAFs in vitro and in TAK adventitial α-SMA positive cells. When AAFs were pretreated with inhibitors against JAK2, STAT3, and Akt, fibrosis was significantly reduced. Furthermore, IL-6/IL-6R promoted mRNA expression of IL-6 and MCP-1 in AAFs. Finally, according to ChIP and reporter assay results, STAT3 was the main transcriptional factor in the fibrosis of AAFs induced by IL-6/IL-6R.

Conclusions: IL-6/IL-6R induces fibrogenesis of AAFs via the JAK2/STAT3 and JAK2/Akt pathways, which provides theoretical evidence for IL-6 as a treatment target in TAK.

MeSH terms

  • Actins / metabolism
  • Adult
  • Adventitia / drug effects
  • Adventitia / immunology
  • Adventitia / metabolism*
  • Adventitia / pathology
  • Anti-Inflammatory Agents / therapeutic use
  • Aorta / drug effects
  • Aorta / immunology
  • Aorta / metabolism
  • Aorta / pathology*
  • Case-Control Studies
  • Cells, Cultured
  • Female
  • Fibrillar Collagens / genetics
  • Fibrillar Collagens / metabolism
  • Fibroblasts / drug effects
  • Fibroblasts / immunology
  • Fibroblasts / metabolism*
  • Fibroblasts / pathology
  • Fibrosis
  • Humans
  • Interleukin-6 / antagonists & inhibitors
  • Interleukin-6 / genetics
  • Interleukin-6 / immunology
  • Interleukin-6 / metabolism*
  • Janus Kinase 2 / metabolism
  • Male
  • Middle Aged
  • Phosphorylation
  • Proto-Oncogene Proteins c-akt / metabolism
  • Receptors, Interleukin-6 / metabolism
  • STAT3 Transcription Factor / metabolism
  • Signal Transduction
  • Takayasu Arteritis / drug therapy
  • Takayasu Arteritis / immunology
  • Takayasu Arteritis / metabolism*
  • Takayasu Arteritis / pathology
  • Transforming Growth Factor beta / metabolism
  • Young Adult

Substances

  • ACTA2 protein, human
  • Actins
  • Anti-Inflammatory Agents
  • Fibrillar Collagens
  • IL6 protein, human
  • IL6R protein, human
  • Interleukin-6
  • Receptors, Interleukin-6
  • STAT3 Transcription Factor
  • STAT3 protein, human
  • Transforming Growth Factor beta
  • JAK2 protein, human
  • Janus Kinase 2
  • Proto-Oncogene Proteins c-akt